By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Antiandrogens > Nilutamide > Nilutamide Dosage
Antiandrogens
https://themeditary.com/dosage-information/nilutamide-dosage-6151.html

Nilutamide Dosage

Drug Detail:Nilutamide (Nilutamide [ nih-lute-ah-mide ])

Drug Class: Antiandrogens Hormones / antineoplastics

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Prostate Cancer

  • Initial dose: 300 mg orally once a day for first 30 days

  • Maintenance dose: 150 mg orally once a day after first 30 days

  • Comments: For maximum benefit, treatment should begin on the same day or the day after surgical castration.

Use: Treatment of metastatic prostate cancer (Stage D2) in combination with surgical castration.

Renal Dose Adjustments

Data not available.

Liver Dose Adjustments

Severe liver impairment: Contraindicated

Precautions

US BOXED WARNING:

  • Interstitial pneumonitis has been reported in 2% of patients in controlled clinical trials. A small study in Japanese subjects showed that 17% of patients developed interstitial pneumonitis. There have been rare postmarketing reports of interstitial changes, including pulmonary fibrosis, that led to hospitalization and death. Symptoms included exertional dyspnea, cough, chest pain, and fever. Most cases occurred within the first 3 months of treatment and most reversed with treatment discontinuation. A routine chest X-ray should be performed prior to treatment initiation; baseline pulmonary function tests may be considered. Patients should be instructed to report new or worsening shortness of breath they experience during treatment. If symptoms occur, treatment should be immediately discontinued until it can be determined if the symptoms are drug-related.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available.

Other Comments

Administration Advice:

  • Take with or without food.
  • Patients should not interrupt dosing or stop treatment without medical consultation.

General:
  • In case of overdose, minimize the absorption of the drug (e.g., with oral administration of activated charcoal), induce vomiting (if that does not occur spontaneously and the patient is alert), and provide general supportive care. Dialysis may not be of benefit since this drug is 80% to 84% protein-bound.

Monitoring:
  • Cardiovascular: QT interval
  • Hepatic: Transaminase levels
  • Respiratory: Chest X-ray (baseline), pulmonary function testing (baseline)

Patient Advice:
  • This drug may cause alcohol intolerance and vision problems. Avoid drinking alcohol, and doing activities such as driving (especially at night and through tunnels) and operating machinery until you know how this drug affects you.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by